Status:
COMPLETED
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
Lead Sponsor:
University of Minnesota
Conditions:
Hepatocellular Carcinoma
Bilirubinemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively norm...
Eligibility Criteria
Inclusion
- hepatocellular carcinoma (HCC)
- Direct or conjugated bilirubin \< 3 mg/dl
- Total bilirubin \> 3 mg/dl
- Willing and able to provide informed consent
- \>18 years of age
Exclusion
- Currently pregnant
- Patients who are surgical or ablation candidates as determined by multidisciplinary hepatobiliary tumor conference.
- Arterial anatomy which would preclude selective transarterial chemoembolization
- Patients who have a INR or platelet count which are not correctable to \<1.8 and \>35,000 respectively
- Patients with extrahepatic metastases
- Patients with portal vein invasion
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03259581
Start Date
January 2 2018
End Date
February 1 2022
Last Update
March 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455